Scans

Tools

Home

Charts

Watchlist

Products

Jeena Sikho Lifecare Ltd

JSLL

NSE

₹369.75-4.78%19 Oct 2026 at 3:58 PM

Reports

Ayurvedic

Jeena Sikho Lifecare Ltd

JSLL

NSE

₹369.75

-4.78%

19 Oct 2026 at 3:58 PM

SOICxStockScans Reports

Ask AI

Ayurvedic

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Jeena Sikho Lifecare is an integrated Ayurvedic hospital company that treats chronic diseases at their root cause rather than just managing symptoms - and it measures itself against mainstream hospital metrics, not alternative-medicine benchmarks. Born from founder Acharya Manish Ji’s personal health struggles and his two-decade immersion in Ayurveda, the business began as a single Chandigarh clinic in 2013 and transformed into a listed hospital chain after opening its first inpatient facility in 2020. The recurring pattern is a capital-light, doctor-driven model where every patient who recovers becomes a lifelong medicine customer, and every medicine customer is a potential hospital admission - a flywheel that funds its own growth without debt.

Business segments

Two engines that feed each other - a network of Ayurvedic hospitals and clinics that treats patients, and a portfolio of over 330 proprietary medicines those patients take home, each generating roughly half the business and each making the other stronger.

1. Ayurveda healthcare services: the hospital network that brings patients in

A hub-and-spoke network of 117-119 facilities across 23 states treats chronic lifestyle diseases through Panchakarma detoxification, with setup costs roughly one-tenth of an allopathy hospital and break-even at just 35% occupancy.

Cheaper to build than conventional hospitals - setup cost per bed is only ₹3-4 lakh, compared to ₹50 lakh to ₹1 crore for allopathy hospitals, because Ayurveda needs no expensive imaging machines or surgical theatres.
Hub-and-spoke keeps costs low - large hospitals in big cities act as hubs, while clinics in nearby small towns refer patients to them, so the company gets patient flow without putting a full hospital in every town.
Paid by governments and insurers - the company is empanelled with CGHS, all seven central armed police forces, ECHS, and major insurers like Star Health and HDFC ERGO, meaning patients can pay cashless rather than out-of-pocket.
Camps convert visitors into inpatients - 72-hour health camps generate ₹30-60 lakh each and convert roughly 30% of attendees into hospital admissions, functioning as both a revenue line and a patient-acquisition channel.
Doctors stay on payroll even in franchises - in the 33-35 franchise clinics, the franchisee bears the property cost but the company employs the Ayurveda doctors and supplies the medicines, so clinical quality and product revenue stay in-house.

2. Ayurvedic products: the medicines patients take home

Over 330 proprietary formulations - all patent medicines, not classical ones - are sold to patients leaving hospitals and to outside customers, with gross margins above 85% and manufacturing entirely outsourced.

No factory, no capex - all manufacturing is done by third-party contractors under loan licenses, so the company avoids tying up capital in plants and carries no manufacturing working-capital burden.
The hospital feeds the pharmacy - every discharged patient leaves with a medicine regimen that generates recurring revenue for months or years, and every medicine customer who calls the support centre is a potential hospital admission.
Priced at a seven-times multiple - the company’s product costing yields a retail price that is about seven times the cost, which is how the vertical sustains its high gross margins.
Now reaching patients through Amazon - a procurement agreement with Theryco Healthcare Solutions in January 2026 authorised listing and selling the company’s products on the Amazon platform, opening a channel beyond its own clinics.
Even pets are covered - the ‘Pet Shuddhi’ line, launched nationally in October 2025, offers Ayurvedic detoxification kits for pets’ stomach, liver, and spleen, backed by clinical validation from the company’s own hospitals.

Group structure and partners

A single listed entity with a UAE subsidiary that is already acquiring clinics, a diagnostic partner embedded in every hospital, and a patient-referral collaboration that pays a share of billing.

UAE subsidiary is buying, not just building - Jeena Sikho International LLC, incorporated in Sharjah in September 2025, has approved the proposal for acquisition of a 51% stake in Back to Roots Ayurveda by Dr. Shyam LLC in Abu Dhabi, with a Share Purchase Agreement yet to be executed.
Diagnostics outsourced to one partner - Chandan Healthcare Limited has a five-year exclusive agreement to set up and run diagnostic centres inside all Jeena Sikho facilities, investing its own capital in equipment and manpower, while Jeena Sikho provides the space and branding.
Patient acquisition through a revenue-share deal - Sat Kartar Life Ltd identifies and funnels patients to Jeena Sikho’s hospitals under a three-year MOU, earning 15% of the bill value on both OPD and IPD cases for as long as the patient remains in active treatment.
A green subsidiary that has not yet started - Jeena Green Resources Private Limited, 51%-owned, was incorporated in March 2025 to make organic manure and cow-urine-based Ayurvedic formulations, but had not commenced business as of its filing date.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹4,575Cr

Close Price

₹368.05

Industry

Ayurvedic

Price To Earnings

19.35

Price To Sales

5.37

Revenue

₹851Cr

Rev Gr TTM

Revenue Growth TTM

56.72%

PAT Gr TTM

PAT Growth TTM

102.99%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	114	116	139	174	190	222	216	224
Growth YoY Revenue Growth YoY%					66.4	91.6	54.8	28.8
Expenses ExpensesCr	74	86	93	96	98	121	138	132
Operating Profit Operating ProfitCr	40	30	46	79	92	101	78	92
OPM OPM%	35.3	25.6	32.9	45.2	48.5	45.4	36.1	41.0
Other Income Other IncomeCr	3	0	0	1	1	3	3	14
Interest Expense Interest ExpenseCr	2	4	3	2	4	3	4	3
Depreciation DepreciationCr	6	8	9	10	10	11	16	15
PBT PBTCr	35	18	34	69	79	89	61	88
Tax TaxCr	9	5	9	17	20	22	16	22
PAT PATCr	27	13	25	51	59	67	45	66
Growth YoY PAT Growth YoY%					120.9	404.2	77.9	28.5
NPM NPM%	23.3	11.4	18.2	29.4	30.9	30.0	20.9	29.4
EPS EPS₹	0.4	0.2	0.4	4.1	4.7	5.4	3.6	5.3

Quarter	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	114	116	139	174	190	222	216	224
Growth YoY Revenue Growth YoY%					66.4	91.6	54.8	28.8
Expenses ExpensesCr	74	86	93	96	98	121	138	132
Operating Profit Operating ProfitCr	40	30	46	79	92	101	78	92
OPM OPM%	35.3	25.6	32.9	45.2	48.5	45.4	36.1	41.0
Other Income Other IncomeCr	3	0	0	1	1	3	3	14
Interest Expense Interest ExpenseCr	2	4	3	2	4	3	4	3
Depreciation DepreciationCr	6	8	9	10	10	11	16	15
PBT PBTCr	35	18	34	69	79	89	61	88
Tax TaxCr	9	5	9	17	20	22	16	22
PAT PATCr	27	13	25	51	59	67	45	66
Growth YoY PAT Growth YoY%					120.9	404.2	77.9	28.5
NPM NPM%	23.3	11.4	18.2	29.4	30.9	30.0	20.9	29.4
EPS EPS₹	0.4	0.2	0.4	4.1	4.7	5.4	3.6	5.3

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	147	205	469	801	851
Growth Revenue Growth%		39.7		70.8	56.7
Expenses ExpensesCr	129	159	328	452	489
Operating Profit Operating ProfitCr	18	46	141	349	363
OPM OPM%	12.3	22.3	30.0	43.6	42.6
Other Income Other IncomeCr	1	3	7	9	22
Interest Expense Interest ExpenseCr	1	1	11	13	15
Depreciation DepreciationCr	3	3	29	48	53
PBT PBTCr	15	44	108	297	316
Tax TaxCr	4	11	28	76	80
PAT PATCr	11	34	80	222	236
Growth PAT Growth%		199.5		177.3	103.0
NPM NPM%	7.6	16.4	17.0	27.7	27.8
EPS EPS₹	11.1	2.8	1.3	17.8	19.0

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	147	205	469	801	851
Growth Revenue Growth%		39.7		70.8	56.7
Expenses ExpensesCr	129	159	328	452	489
Operating Profit Operating ProfitCr	18	46	141	349	363
OPM OPM%	12.3	22.3	30.0	43.6	42.6
Other Income Other IncomeCr	1	3	7	9	22
Interest Expense Interest ExpenseCr	1	1	11	13	15
Depreciation DepreciationCr	3	3	29	48	53
PBT PBTCr	15	44	108	297	316
Tax TaxCr	4	11	28	76	80
PAT PATCr	11	34	80	222	236
Growth PAT Growth%		199.5		177.3	103.0
NPM NPM%	7.6	16.4	17.0	27.7	27.8
EPS EPS₹	11.1	2.8	1.3	17.8	19.0

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	10	14	25	25
Reserves ReservesCr	26	112	231	442
Current Liabilities Current LiabilitiesCr	24	25	73	105
Non Current Liabilities Non Current LiabilitiesCr	1	1	89	102
Total Liabilities Total LiabilitiesCr	62	151	419	674
Current Assets Current AssetsCr	22	77	135	341
Non Current Assets Non Current AssetsCr	40	74	284	333
Total Assets Total AssetsCr	62	151	419	674

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	10	14	25	25
Reserves ReservesCr	26	112	231	442
Current Liabilities Current LiabilitiesCr	24	25	73	105
Non Current Liabilities Non Current LiabilitiesCr	1	1	89	102
Total Liabilities Total LiabilitiesCr	62	151	419	674
Current Assets Current AssetsCr	22	77	135	341
Non Current Assets Non Current AssetsCr	40	74	284	333
Total Assets Total AssetsCr	62	151	419	674

Consolidated

Standalone

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	16	15	85	254
Investing Cash Flow Investing Cash FlowCr	-18	-33	-64	-202
Financing Cash Flow Financing Cash FlowCr	-5	48	-22	-59
Net Cash Flow Net Cash FlowCr	-7	29	-2	-7
Free Cash Flow Free Cash FlowCr	3	-15	45	221
CFO To PAT CFO To PAT%	146.1	43.3	105.7	114.5
CFO To EBITDA CFO To EBITDA%	90.6	31.8	60.1	72.6

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	16	15	85	254
Investing Cash Flow Investing Cash FlowCr	-18	-33	-64	-202
Financing Cash Flow Financing Cash FlowCr	-5	48	-22	-59
Net Cash Flow Net Cash FlowCr	-7	29	-2	-7
Free Cash Flow Free Cash FlowCr	3	-15	45	221
CFO To PAT CFO To PAT%	146.1	43.3	105.7	114.5
CFO To EBITDA CFO To EBITDA%	90.6	31.8	60.1	72.6

Consolidated

Standalone

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr		400	27,131	6,711	4,575
Price To Earnings Price To Earnings		11.8	67.9	30.3	19.4
Price To Sales Price To Sales		1.9	57.8	8.4	5.4
Price To Book Price To Book		3.2	21.2	14.4	9.8
EV To EBITDA EV To EBITDA		8.1	193.6	19.3	13.4
Profitability Ratios Profitability Ratios
GPM GPM%	87.6	87.3	87.2	88.5	88.5
OPM OPM%	12.3	22.3	30.0	43.6	42.6
NPM NPM%	7.6	16.4	17.0	27.7	27.8
ROCE ROCE%	36.9	35.5	31.7	52.2	52.2
ROE ROE%	30.7	26.6	31.2	47.5	47.5
ROA ROA%	18.2	22.2	19.1	32.9	32.9
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2022	Mar 2023	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr		400	27,131	6,711	4,575
Price To Earnings Price To Earnings		11.8	67.9	30.3	19.4
Price To Sales Price To Sales		1.9	57.8	8.4	5.4
Price To Book Price To Book		3.2	21.2	14.4	9.8
EV To EBITDA EV To EBITDA		8.1	193.6	19.3	13.4
Profitability Ratios Profitability Ratios
GPM GPM%	87.6	87.3	87.2	88.5	88.5
OPM OPM%	12.3	22.3	30.0	43.6	42.6
NPM NPM%	7.6	16.4	17.0	27.7	27.8
ROCE ROCE%	36.9	35.5	31.7	52.2	52.2
ROE ROE%	30.7	26.6	31.2	47.5	47.5
ROA ROA%	18.2	22.2	19.1	32.9	32.9
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	JSLL	KERALAYUR	SOURCENTRL
Market CapitalizationMkt CapCr	4,575	188	70
Close PriceClose₹	368.05	144.85	109.00
IndustryIndustry	Ayurvedic	Ayurvedic	Ayurvedic
Price To EarningsPE	19.35		20.64
Price To SalesPS	5.37	1.39	1.00
RevenueRevenueCr	851	136	70
Revenue Growth TTMRev Gr TTM%	56.7%	11.7%
PAT Growth TTMPAT Gr TTM%	103.0%	-113.4%

	JSLL	KERALAYUR	SOURCENTRL
Market CapitalizationMkt CapCr	4,575	188	70
Close PriceClose₹	368.05	144.85	109.00
IndustryIndustry	Ayurvedic	Ayurvedic	Ayurvedic
Price To EarningsPE	19.35		20.64
Price To SalesPS	5.37	1.39	1.00
RevenueRevenueCr	851	136	70
Revenue Growth TTMRev Gr TTM%	56.7%	11.7%
PAT Growth TTMPAT Gr TTM%	103.0%	-113.4%